Board of Directors

Hank Nordhoff

Executive Chairman

Mr. Nordhoff has an exceptional depth of experience and expertise in diagnostic, pharmaceutical, operations and business. He served as president and CEO of Gen-Probe for 15 years until his retirement in May 2009. In addition to Gen-Probe, he served as CEO of three successful biopharmaceutical companies. Read more

At the beginning of his career, Nordhoff spent 16 years at Pfizer in senior positions and lived (and worked) in Europe and Asia for 11 years. He holds a B.A. in International Relations and Political Economy from Johns Hopkins University and an MBA degree from Columbia University.

Herb Boyer, PhD


Dr. Boyer co-founded Genentech in 1976 and served as a director of the company until its 2008 acquisition by Roche. He also was a vice president of the company from 1976 to 1990. Dr. Boyer also served on the board of Allergan for 19 years, 12 years as vice chairman and three years as chairman. Read more

In addition, Dr. Boyer was a professor at the University of California, San Francisco and an investigator for the Howard Hughes Medical Institute (HHMI). He is an elected member of the National Academy of Sciences (NAS) and a fellow in the American Academy of Arts and Sciences (AAAS). Dr. Boyer received the Albert Lasker Basic Medical Research Award in 1980 and the Shaw Prize for life science and medicine and the Albany Medical Center Prize in Medicine and Biomedical Research, each in 2004.

Eric Topol, MD


Dr. Topol is a visionary and world-expert on precision medicine and genomics. He is currently Director of STSI, Professor of Genomics at The Scripps Research Institute, Chief Medical Advisor of AT&T and Editor-in-Chief for Medscape. Read More

Dr. Topol spearheaded the implementation of routine genotyping of CYP2C19, the major gene implicated in Plavix metabolism in patients undergoing stinting at Scripps. He was elected to the Institute of Medicine of the National Academy of Sciences and is one of the top 10 most cited researchers in medicine (Dr. Topol has published 1100 peer-reviewed articles and over 30 medical textbooks). His popular book, “The Creative Destruction of Medicine,” examined the impact of both the genomic and wireless revolutions on the health care system.

Andy von Eschenbach, MD


Dr. von Eschenbach currently serves as president of Samaritan Health Initiatives and as an adjunct professor at University of Texas MD Anderson Cancer Center. From September 2005 to January 2009, he served as commissioner of the U.S. FDA, Read more

where he championed an agenda to modernize the FDA by process improvement of the regulatory pathway for drugs and medical devices and by fostering creative projects, including the FDA’s Critical Path Initiative. Under his leadership, the FDA experienced dramatic increases in resources enabling implementation of many new programs designed to strengthen the FDA in its mission to protect and promote public health. Prior to joining the FDA, Dr. von Eschenbach served as the director of the National Cancer Institute (NCI) and had an outstanding and award-recognized career over three decades as a physician, surgeon, oncologist and executive. In 2006, Dr. von Eschenbach was named one of Time magazine’s “100 most influential people to shape the world.”